Camlin Fine Sciences files FY26 Annual Report; consolidated PAT at Rs 23.5 cr

Revenue DeclineEbitda Margin CompressionExceptional ItemPat NegativeResults View source PDF

CAMLINFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.9%1-day move

₹122.95

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————+0.9-1.6-2.4+1.7+3.9—————

Up moveDown movePending

AI summary

Camlin Fine Sciences filed its FY 2025-26 Annual Report. Consolidated revenue grew to Rs 1,723.31 cr from Rs 1,628.69 cr, but EBITDA fell to Rs 106.88 cr from Rs 216.04 cr on US tariffs and weak demand. Standalone revenue slipped to Rs 837.92 cr with a loss of Rs 32.97 cr. Consolidated PAT turned positive at Rs 23.54 cr, helped by Rs 55.07 cr gain from discontinued ops. AGM on Aug 11, 2026. No dividend since FY17.

Likely market impact

Mixed year: consolidated revenue up but EBITDA halved on weak demand and tariffs; core business still in loss; no dividend for shareholders.